NCT04128501View on ClinicalTrials.gov

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

PHASE2RecruitingINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

May 5, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute LeukemiaT Acute Lymphoblastic LeukemiaTherapy-Related Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given SC

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER